Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 955-970

  Jung, Frédéric H ^a   Pasquet, Georges ^a   Lambert Van Der Brempt, Christine ^a   Lohmann, Jean Jacques M ^a   Warin, Nicolas ^a   Renaud, Fabrice ^a   Germain, Hervé ^a   De Savi, Chris ^a   Roberts, Nicola ^a   Johnson, Trevor ^a   Dousson, Cyril ^a   Hill, George B ^a   Mortlock, Andrew A ^a   Heron, Nicola ^a   Wilkinson, Robert W ^a   Wedge, Stephen R ^a   Heaton, Simon P ^a   Odedra, Rajesh ^a   Keen, Nicholas J ^a   Green, Stephen ^a   Brown, Elaine ^a   Thompson, Katherine ^a   Brightwell, Stephen ^a   more..

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; ENZYME INHIBITOR; HISTONE H3; PHOSPHATE; PRODRUG; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE; THIAZOLOQUINAZOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTROMERE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; IMPLANTATION; MAMMAL CELL; MITOSIS SPINDLE; MOUSE; NONHUMAN; SPINDLE CELL; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TELOPHASE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HISTONES; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PHOSPHORIC ACID ESTERS; PRODRUGS; PROTEIN-SERINE-THREONINE KINASES; QUANTUM THEORY; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 32344437258     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050786h     Document Type: Article

References (56)

1. Bischoff, J. R.; Plowman, G. D. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 1999, 9, 454-459.
2. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S. M.; Novotny, M.; Salomon, D. J.; Plowman, G. D. A homologue of Drosophila Aurora kinase is oncogenic and amplified in colorectal cancers. EMBO J. 1998, 17, 3052-3065.
3. Zhou, H.; Kuang, J.; Zhong, L.; Kuo, W. L.; Gray, J. W.; Sahin, A.; Brinkley, B. R.; Sen, S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20, 189-193.
4. Carmena, M.; Earnshaw, W. C. The cellular geography of Aurora kinases. Nat. Rev. Mol. Cell Biol. 2003, 4, 842-854.
5. Murata-Hori, M.; Wang, Y. The kinase activity of Aurora B is required for kinetochore-microtubule interactions in mitosis. Curr. Biol. 2002, 12, 894-899.
6. Adams, R. R.; Maiato, H.; Earnshaw, W. C.; Carmena, M. Essential role of Drosophila inner centromere protein (INCENP) and Aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J. Cell. Biol. 2001, 153, 865-880.
7. Biggins, S.; Murray, A. W. The budding yeast protein kinase Ipl1/Aurora allows the absence of tension to activate the spindle checkpoint. Genes Dev. 2001, 15, 3118-3129.
8. Dietchfield, C.; Johnson, V. L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor, S. S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell. Biol. 2003, 161, 267-280.
9. Bishop, J. D.; Schumacher, J. M. Phosphorylation of the carboxyl terminus of inner centromere protein (INCENP) by Aurora B kinase stimulates Aurora B kinase activity. J. Biol. Chem. 2002, 277, 27577-27580.
10. Tanaka, T. U.; Rachidi, N.; Janke, C.; Pereira, G.; Glova, M.; Schiebel, E.; Stark, M. J. R.; Nasmyth, K. Evidence that Ipl1-Sli15 (Aurora kinase-INCENP) complexe promotes bi-orientation by altering kinetochore-spindle pole connections. Cell 2002, 108, 317-329.
11. Shimoda, S. L.; Solomon, F. Integrating functions at the kinetochore. Cell 2002, 109, 9-12.
12. Wheatley, S. P.; Carvalho, A.; Vagnarelli, P.; Earnshaw, W. C. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr. Biol. 2001, 11, 886-890.
13. Bolton, M. A.; Lan, W.; Powers, S. E.; McCleland, M. L.; Kuang, J.; Stukenberg, P. T. Aurora B Kinase exists in a complex with Survivin and INCENP and its kinase activity is stimulated by Survivin binding and phosphorylation. Mol. Biol. Cell 2002, 13, 3064-3077.
14. Adams, R. R.; Carmena, M.; Earnshaw, W. C. Chromosomal passengers and the (Aurora) ABCs of mitosis. Trends Cell Biol. 2001, 11, 49-54.
15. Chen, J.; Jin, S.; Tahir, S. K.; Zhang, H.; Liu, X.; Sarthy, A. V.; McGonigal, T. P.; Liu, Z.; Rosenberg, S. H.; Ng, S. C. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J. Biol. Chem. 2003, 278, 486.
16. -/- cells. EMBO J. 2002, 21, 483-492.
17. Anaud, S.; Penrhyn-Lowe, S.; Venkitaraman, A. R. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 2003, 3, 51-62.
18. Jallepalli, P. V.; Lengauer, C. Chromosome segregation and cancer: Cutting through the mystery. Nat. Rev. Cancer 2001, 1, 109-117.
19. Hsu, J. Y.; Sun, Z. W.; Li, X.; Reuben, M.; Tatchell, K.; Bishop, D. K.; Grushcow, J. M.; Brame, C. J.; Caldwell, J. A.; Hunt, D. F.; Lin, R.; Smith, M. M.; Allis, C. D. Mitotic phosphorylation of histone H3 is governed by Ipl1/Aurora kinase and Glc 7/PP1 phosphatase in budding yeasts and nematodes. Cell 2000, 102, 279-291.
20. Giet, R.; Glover, D. M. Drosophila Aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J. Cell. Biol. 2001, 152, 669-682.
21. Crosio, C.; Fimia, G. M.; Loury, R.; Kimura, M.; Okano, Y.; Zhou, H.; Sen, S.; Allis, C. D.; Sassone-Corsi, P. Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mamelian Aurora kinases. Mol. Cell. Biol. 2002, 22, 874-885.
22. Giet, R.; Prigent, C. Aurora/Ipl1p-related kinases, a new family of mitotic serine-threonine kinases. J. Cell Sci. 1999, 112, 3591-3601.
23. Tatsuka, M.; Katayama, H.; Ota, T.; Tanaka, T.; Odashima, S.; Suzuki, F.; Terada, Y. Multinuclearity and increased ploidy caused by overexpression of the Aurora-and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res. 1998, 58, 4811-4816.
24. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumour growth in vivo. Nat. Med. 2004, 10, 262-267.
25. Hauf, S.; Cole, R. W.; LaTerra, S.; Zimmer, C.; Schnapp, G.; Walter, R.; Heckel, A.; Van Meel, J.; Rieder, C. L.; Peters, J.-M. The small molecule Hesperadin reveals a role for Aurora B in connecting kinetochore-microtubule attachement and in maintaining the spindle assembly checkpoint. J. Cell Biol. 2003, 161, 281-294.
26. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domaine of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
27. Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakanatan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A. 6-substituted-4-(3- bromophenylamino)quinazolines as putative irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumour activity. J. Med. Chem. 2001, 44, 2719-2734.
28. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(Phenylamino)pyrazolo[3,4- d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
29. Mortlock, A. A.; Jung, F. H. Preparation of substituted quinazoline derivatives and their use as inhibitors of Aurora-2 kinase. WO 2002000649 A1 20020103. CAN 136:85826.
30. Jung, F. H.; Pasquet, G. R. Preparation of substituted quinazoline derivatives as inhibitors of Aurora kinases. WO 2003055491 A1 20030710. CAN 139:101142.
31. Mortlock, A. A.; Keen, N. J.; Jung, F. H.; Heron, N. M.; Foote, K. M.; Wilkinson, R.; Green, S. Progress in the Development of Selective Inhibitors of Aurora kinases. Curr. Top. Med. Chem. 2005, 5, 199-213.
32. Heron, N. M.; Anderson, M.; Blowers, D. P.; Breed, J.; Eden, J. M.; Green, S.; Hill, G. B.; Johnson, T.; Jung, F. H.; McMiken, H. H. J.; Mortlock, A. A.; Pannifer, A. D.; Pauptit, R. A.; Pink, J.; Roberts, N. J.; Rowsell, S. SAR and Inhibitor Complex Structure Determination of a Novel Class of Potent and Specific Aurora Kinase Inhibitors. Bioorg. Med. Chem. Lett. In press.
33. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A. 11.3; Gaussian, Inc.: Pittsburgh, PA, 2002.
34. Pierce, A. C.; ter Haar, E.; Binch, H. M.; Kay, D. P.; Patel, S. R.; Li, P. CH...O and CH...N Hydrogen Bonds in Ligand Design: A Novel Quinazolin-4-ylthiazol-2-ylamine Protein Kinase Inhibitor. J. Med. Chem. 2005, 48, 1278-81.
35. Bayliss, R.; Sardon, T.; Vernos, I.; Conti, E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell. 2003, 12, 851-862.
36. Nowakowski, J.; Cronin, C. N.; McRee, D. E.; Knuth, M. W.; Nelson, C. G.; Pavletich, N. P.; Rogers, J.; Sang, B. C.; Scheibe, D. N.; Swanson, R. V.; Thompson, D. A. Structures of the cancer-related aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 2002, 10, 1659-1667.
37. Cheetham, G. M. T.; Knegtel, R. M. A.; Coll, J. T.; Renwick, S. B.; Swenson, L.; Weber, P.; Lippke, J. A.; Austen, D. A. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. 2002, 277, 42419-42422.
38. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
39. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of P38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
40. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Cancer Genome Project; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell. 2004, 116 (6), 855-67.
41. Sessa, F.; Mapelli, M.; Ciferri, C.; Tarricone, C.; Araces, L. B.; Schneider, T. R.; Stukenberg, P. T.; Musacchio, A. Mechanism of Aurora B Activation by INCENP and Inhibition by Hesperadin. Cell. 2005, 18 (3), 379-91.
42. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Plé, P. A.; Lohmann, J. J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curven, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
43. Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curven, J. O. Novel 4-anilinoquinazolines with C7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
44. Pandey, A.; Volkots, D. L.; Seroogy, J. M.; Rose, J. W.; Yu, J. C.; Lambing, J. L.; Hutchaleelaka, A.; Hollenbach, S. J.; Abe, K.; Giese, N. A.; Scarborough, R. M. Identification of orally active, potent and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J. Med. Chem. 2002, 45, 3772-3793.
45. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D. H.; Vincent, P. W.; Elliot, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of epidermal growth factor receptor. 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43, 1380-1397.
46. Erlenmeyer, H.; Herzfeld, L.; Prijs, B. Zur synthese von 2-aminothiazolderivaten. Helv. Chem. Acta 1955, 38, 1291-1294.
47. Molina, P.; Conesa, C.; Velasco, M. D. Iminophosphorane-mediated synthesis of 2-aminoimidazole derivatives. Synthesis 1996, 1459-1462.
48. Gompper, R.; Christmann, O. Studies in the azole series. Chem. Ber. 1959, 92, 1944-1949.
49. El-Kerdawy, M. M.; El-Emam, A. A.; El-Subbagh, H. I.; Abushanab, E. Synthesis of substituted 4H-thiazolo[4,5-b][1]benzothiopyran-4-ones as possible schistosomicidal agents. Monatsch. Chem. 1989, 120, 991-995.
50. Mahajanshetti, C. S.; Basanagoudar, L. D. A facile nucleophilic displacement of bromine in 2-amino-4-methyl-5-bromothiazole by a thiophenoxide anion. Can. J. Chem. 1967, 45, 1807-1810.
51. Harada, H.; Watanuki, S.; Takuwa, T.; Kawaguchi, K.; Okazaki, T.; Hirano, Y.; Saitoh, C. Preparation of dicyanopyridine derivatives as high-conductance calcium-sensitive potassium channel openers. WO 20026237 A1 20020124. CAN 136:118474.
52. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Hennequin, L. F.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000, 60, 970-975.
53. SYBYL 6.9.1; Tripos Inc., St. Louis, MO.
54. AMPAC, version 6.55 A.; Semichem Inc.: Kansas City, MO, 1999.
55. Fancelli, D.; Berta, D.; Bindi, S.; Cameron, A.; Cappella, O.; Carpinelli, P.; Catana, C.; Forte, B.; Giordano, P.; Giorgini, M. L.; Mantegani, S.; Marsiglio, A.; Meroni, M.; Moll, J.; Pittalà, V.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Varasi, M.; Vulpetti, A.; Vianello, P. Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition. J. Med. Chem. 2005, 48, 3080-3084.
56. McWeeny, R. Methods of Molecular Quantum Mechanics, 2nd ed.; Elsvier Academic Press: New York, 1992.